Shots:
- Amneal Pharmaceuticals has entered into a definitive agreement to acquire 100% of Kashiv BioSciences, accelerating its biosimilar pipeline & strengthening US commercial position
- As per the deal, Amneal will acquire Kashiv for $375M cash & $375M equity at closing, plus up to ~$350M in regulatory milestone payments, potential royalties tied to commercial milestones, & funding of operations through closing; closing is expected in the H2’26
- The proposed deal will establish a unique global biosimilars platform by integrating Kashiv BioSciences’ development & manufacturing expertise with Amneal Pharmaceuticals’ commercial capabilities
Ref: Globenewswire | Image: Kashiv | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
